Buy Reta Glp 3 (Retatrutide) 10mg Online Research Peptide
Retatrutide is a next-generation GLP-1/GIP/glucagon triple receptor agonist developed by Eli Lilly. It simultaneously activates three metabolic receptors — GLP-1R, GIPR, and GCGR — making it one of the most studied compounds in obesity and metabolic dysfunction research. This 10mg vial provides research-grade retatrutide peptide at ≥99% purity, verified by HPLC and MS/MS analysis.
Research Background
A Phase 2 clinical trial published in the New England Journal of Medicine (2023) demonstrated participants receiving retatrutide achieved up to 24.2% mean weight reduction over 48 weeks — the highest reduction reported for any investigational compound in its class at that time. Research continues into its effects on hepatic fat, lipid profiles, and insulin sensitivity. Phase 3 trials (TRIUMPH program) are ongoing as of 2026.
For a full overview of retatrutide’s mechanism, clinical trial data, dosage reference, and comparison with tirzepatide, see our Retatrutide Peptide Research Guide. Also available in 20mg, 30mg, and 40mg vials.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 10mg per vial
- Storage: −20°C, protected from light
- CAS Number: 2381272-12-2
Certificate of Analysis
All retatrutide vials are third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
